Auris Medical (EARS) Receives Daily News Impact Score of 0.15

News coverage about Auris Medical (NASDAQ:EARS) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Auris Medical earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned news headlines about the biotechnology company an impact score of 47.5203753227658 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the headlines that may have effected Accern Sentiment’s rankings:

Shares of Auris Medical (EARS) traded up $0.02 during midday trading on Monday, reaching $0.50. The company’s stock had a trading volume of 2,538,500 shares, compared to its average volume of 501,236. The company has a current ratio of 1.86, a quick ratio of 1.86 and a debt-to-equity ratio of -14.04. The company has a market cap of $24.33, a price-to-earnings ratio of -0.78 and a beta of 0.59. Auris Medical has a 52-week low of $0.38 and a 52-week high of $1.39.

Separately, Zacks Investment Research raised Auris Medical from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a research note on Wednesday, August 30th.

TRADEMARK VIOLATION NOTICE: “Auris Medical (EARS) Receives Daily News Impact Score of 0.15” was posted by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at

Auris Medical Company Profile

Auris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration.

Insider Buying and Selling by Quarter for Auris Medical (NASDAQ:EARS)

Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit